Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

(2011) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

(2011) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

(2011) Irfan Vardarli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

DPP-4 inhibition and islet function

(2011) Bo Ahrén   Journal of Diabetes Investigation

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

(2011) Atsunori Kashiwagi et al.   Journal of Diabetes Investigation

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

(2011) Akira Kubota et al.   Journal of Diabetes Investigation

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

(2011) Daisuke Yabe et al.   Journal of Diabetes Investigation

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

GIP and GLP-1, the two incretin hormones: Similarities and differences

(2010) Yutaka Seino et al.   Journal of Diabetes Investigation

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

(2010) Daisuke Yabe et al.   Journal of Diabetes Investigation

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2009) Richard E. Pratley et al.   CURRENT MEDICAL RESEARCH AND OPINION

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

(2009) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

(2009) K. Aaboe et al.   DIABETES OBESITY & METABOLISM

Hypoglycaemia with Oral Antidiabetic Drugs

(2009) Veronika Vlckova et al.   DRUG SAFETY

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2009) Richard E Pratley   EXPERT OPINION ON PHARMACOTHERAPY

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

(2009) Joshua J. Neumiller   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice

(2009) Nancy Bohannon   POSTGRADUATE MEDICINE

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis

(2008) M. Bodmer et al.   DIABETES CARE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE